2 Sleep Apnea Stocks in Focus Today

Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country. LLY is up 1.7% at $480.55 at last glance, while shares of rival ResMed Inc (NYSE:RMD), which creates continuous positive airway pressure (CPAP) devices for sleep apnea, was last seen down 5% at $225.44 after the news. On the charts, LLY posted a much-needed rebound last sessi ...